Advanced

Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran.

Schött, Ulf LU ; Sollén, C; Axelsson, K; Rugarn, P and Allvin, I (1995) In Acta Anaesthesiologica Scandinavica 39(5). p.592-598
Abstract
The blood loss-reducing effect of desmopressin during dextran therapy was studied in a double-blind fashion in 79 elderly but otherwise healthy patients with preoperative normal bleeding time undergoing total hip replacement for primary coxarthrosis. An infusion of desmopressin (0.3 microgram/kg body weight) or placebo was randomly administered immediately after administration of spinal anaesthesia and six hours later. Haemostasis was evaluated on the basis of vWF: ristocetin cofactor activity, FVIII: C activity, human tissue plasminogen activator (tPA) plasminogen activator inhibitor type (PAI), beta-thromboglobuline (beta TG) and a clot impedance test (Sonoclot). There were no statistically significant differences (P > 0.05) in mean... (More)
The blood loss-reducing effect of desmopressin during dextran therapy was studied in a double-blind fashion in 79 elderly but otherwise healthy patients with preoperative normal bleeding time undergoing total hip replacement for primary coxarthrosis. An infusion of desmopressin (0.3 microgram/kg body weight) or placebo was randomly administered immediately after administration of spinal anaesthesia and six hours later. Haemostasis was evaluated on the basis of vWF: ristocetin cofactor activity, FVIII: C activity, human tissue plasminogen activator (tPA) plasminogen activator inhibitor type (PAI), beta-thromboglobuline (beta TG) and a clot impedance test (Sonoclot). There were no statistically significant differences (P > 0.05) in mean blood loss or transfusion requirements between the placebo and the desmopressin group. There was a significantly increase (P < 0.01) both in vWF: ristocetin cofactor and in FVIII: C activity after both infusions of desmopressin compared with placebo. There was no significant difference in beta TG, tPA, PAI or Sonoclot analysis between the groups. In conclusion, desmopressin did not reduce blood loss in patients undergoing total hip replacement. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Dextrans: therapeutic use, Deamino Arginine Vasopressin: therapeutic use, Surgical: prevention & control, Blood Loss, Deamino Arginine Vasopressin: adverse effects, Hemostatics: therapeutic use, Thromboembolism: prevention & control
in
Acta Anaesthesiologica Scandinavica
volume
39
issue
5
pages
592 - 598
publisher
Wiley-Blackwell
external identifiers
  • pmid:7572006
  • scopus:0029064630
ISSN
0001-5172
language
English
LU publication?
yes
id
417a5aea-b0f4-41c7-8c0d-9b49d1f15a0a (old id 3634377)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/7572006?dopt=Abstract
date added to LUP
2013-07-02 13:07:33
date last changed
2017-07-23 04:53:03
@article{417a5aea-b0f4-41c7-8c0d-9b49d1f15a0a,
  abstract     = {The blood loss-reducing effect of desmopressin during dextran therapy was studied in a double-blind fashion in 79 elderly but otherwise healthy patients with preoperative normal bleeding time undergoing total hip replacement for primary coxarthrosis. An infusion of desmopressin (0.3 microgram/kg body weight) or placebo was randomly administered immediately after administration of spinal anaesthesia and six hours later. Haemostasis was evaluated on the basis of vWF: ristocetin cofactor activity, FVIII: C activity, human tissue plasminogen activator (tPA) plasminogen activator inhibitor type (PAI), beta-thromboglobuline (beta TG) and a clot impedance test (Sonoclot). There were no statistically significant differences (P &gt; 0.05) in mean blood loss or transfusion requirements between the placebo and the desmopressin group. There was a significantly increase (P &lt; 0.01) both in vWF: ristocetin cofactor and in FVIII: C activity after both infusions of desmopressin compared with placebo. There was no significant difference in beta TG, tPA, PAI or Sonoclot analysis between the groups. In conclusion, desmopressin did not reduce blood loss in patients undergoing total hip replacement.},
  author       = {Schött, Ulf and Sollén, C and Axelsson, K and Rugarn, P and Allvin, I},
  issn         = {0001-5172},
  keyword      = {Dextrans: therapeutic use,Deamino Arginine Vasopressin: therapeutic use,Surgical: prevention & control,Blood Loss,Deamino Arginine Vasopressin: adverse effects,Hemostatics: therapeutic use,Thromboembolism: prevention & control},
  language     = {eng},
  number       = {5},
  pages        = {592--598},
  publisher    = {Wiley-Blackwell},
  series       = {Acta Anaesthesiologica Scandinavica},
  title        = {Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran.},
  volume       = {39},
  year         = {1995},
}